1)HLX43是全球潜在BICPD-L1ADC，肺癌、胃癌、胸腺癌等多适应症临床在研。继2025年9月WCLC大 会更新1期数据后(共计56例)，2025年11月2日公司公布了HLX43治疗NSCLC的关键更新数据，首次合并 了国际多中心II期临床结果，总人群疗效显著：鳞状NSCLC患者(2mg/kg，n=33)ORR为33.3%，非鳞状 NSCLC患者(2.5mg/kg，n=35)ORR为48.6%。同时，HLX43不依赖生物标志物筛选：PD-L1阴性(TPS＜ 1%，n=43)患者ORR为39.5%，提示疗效不受PD-L1表达限制，有望覆盖更广泛群体。此外，HLX43安 全性良好：血小板计数减少仅1.7%，血液学毒性较低。9.8%患者报告了irAE，2.9%患者出现免疫相关 性肺病，但观察到显著治疗获益：40%的cORR及100%的肿瘤缩小率，提示其疗效经由小分子毒素以及 免疫机制共同介导。同时，2025ESMOAsia披露：HLX43在晚期宫颈癌II期临床研究中展现了优异的初 步临床疗效，ORR为37.9%，DCR为72.4%，且安全性可控。2)HLX22：与曲妥珠单抗联用更优效、安 全，HLX22联合 ...

智通财经APP获悉，中国银河证券发布研报称，复宏汉霖(02696)创立于2010年，聚焦血液瘤、实体瘤、 自身免疫疾病等领域，是国内最早布局生物类似药的企业。2018年起，公司积极与海外厂商就生物类似 药、创新药的出海达成合作，以曲妥珠单抗为代表的产品已在全球50多个国家和地区获批上市。首次覆 盖，给予"推荐"评级。 1）HLX43是全球潜在BICPD-L1ADC，肺癌、胃癌、胸腺癌等多适应症临床在研。继2025年9月WCLC 大会更新1期数据后（共计56例），2025年11月2日公司公布了HLX43治疗NSCLC的关键更新数据，首 次合并了国际多中心II期临床结果，总人群疗效显著：鳞状NSCLC患者（2mg/kg，n=33）ORR为 33.3%，非鳞状NSCLC患者（2.5mg/kg，n=35）ORR为48.6%。同时，HLX43不依赖生物标志物筛选： PD-L1阴性（TPS＜1%，n=43）患者ORR为39.5%，提示疗效不受PD-L1表达限制，有望覆盖更广泛群 体。此外，HLX43安全性良好：血小板计数减少仅1.7%，血液学毒性较低。9.8%患者报告了irAE， 2.9%患者出现免疫相关性肺病，但观察到 ...

| 股份代號: | 02696 | | --- | --- | | 上市法國名稱: | 上海復宏漢霖生物技術股份有限公司 - H股 | | 日期 (日 / 月 / 年): | 16/11/2024 - 16/12/2025 | | 表格序號 | 大股東/董事/最高行政人員名 作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | | 持有權益的股份數目 佔已發行的有關事件的日 相關法團 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 股份數目 | | | ( 請参関上述 * 註 有投票權股 期 (日 / 月 / | | | | | | | | | 份百分比 年) | | | CS20251215E00106 | GIC Private Limited | 1001(L) | | 88.200(L) | HKD 64.7061 | 8.208.400(L) | 5.02(L)11/12/2025 | 格隆汇12月16日丨根据联交所最新权益披露资料显示，2025年12月11日，复宏汉霖(02696.HK)获GIC Private ...

据港交所披露，新加坡政府投资公司(GIC Private Limited)于12月11日以每股均价64.7061港元增持复宏 汉霖(2696.HK)8.82万股H股股份，价值约570.71万港元。增持后，新加坡政府投资公司最新持股数目为 820.84万股股份，持股比例由4.97%升至5.02%。 继Point72 Associates、博裕资本和泰康保险举牌后，复宏汉霖再获新加坡政府投资公司举牌，体现国际 资金对公司经营稳健性与成长潜力的信心。 ...

12月15日，受上周五美股大跌影响，港股股指震荡调整，截止午盘，恒生指数跌0.92%报25737.85点， 恒生科技指数跌1.79%报5537.11点，国企指数跌1.2%报8970.29点，红筹指数跌0.3%报4137.97点。 中远海能(01138.HK)：与大连中远海运重工、扬州中远海运重工及广东中远海运重工就建造一艘乙烯船 和十八艘油轮订立造船合约，总代价为人民币78.82亿元。 盘面上，大型科技股普跌，阿里巴巴跌2.73%，腾讯控股跌1.54%，京东集团跌1.12%，小米集团跌 2.28%，网易跌0.18%，美团跌1.07%，快手跌3.85%，哔哩哔哩跌1.12%；保险股走强，中国平安创逾四 年新高；生物医药板块走弱，百济神州跌超6%；芯片股跌幅居前，华虹半导体跌超6%。 企业新闻 众安在线(06060.HK)：前11月累计原保险保费收入总额约为人民币329.04亿元。 富力地产(02777.HK)：前11个月总销售收入约127亿元，同比增长24.63%。 亿达中国(03639.HK)：前11个月合约销售金额约为6.81亿元，同比减少23.22% 卡森国际(00496.HK)：与供应商订立钢结构采购合 ...

港股生物技术板块持续走低，歌礼制药(01672.HK)跌超8%，圣诺医药(02257.HK)跌超6%，百济神州 (06160.HK)、复宏汉霖(02696.HK)等跟跌。 本文源自：金融界AI电报 ...

12月15日，港股集体低开，其中恒生指数跌1%，报25718.14点，恒生科技指数跌1.34%，报5562.67点， 国企指数跌1.09%，报8980.13点，红筹指数跌0.06%，报4148.1点。 卡森国际(00496.HK)：与供应商订立钢结构采购合约，涉资4353.66万元。 拨康视云-B(02592.HK)：成功举行CBT-004的第2期临床试验后会议。 复宏汉霖(02696.HK)：汉斯状®联合化疗用于胃癌新辅助/辅助治疗的上市注册申请获国家药监局受理， 并已纳入优先审评 盘面上，大型科技股普遍走低，阿里巴巴跌2.14%，腾讯控股跌1.62%，京东集团跌0.61%，小米集团跌 1.54%，网易跌1.19%，美团跌0.78%，快手跌1.7%，哔哩哔哩跌1.64%；创新药板块多股低开，歌礼制 药跌5.92%，昭衍新药跌3.48%；中资券商股集体下跌，光大证券跌超1%；港股汽车板块多股低开，理 想汽车跌超2%，小鹏汽车跌近2%，比亚迪股份、零跑汽车、蔚来汽车等跟跌。另外，三胎概念股、光 伏股多数上涨，明星股锦欣生殖涨约3%。 企业新闻 中远海能(01138.HK)：与大连中远海运重工、扬州中远海运重工及 ...

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, recommending a focus on innovative drugs and sectors with improving performance, such as medical devices and upstream segments [3][4]. Core Insights - The pharmaceutical sector experienced a decline of 1.0% this week, ranking 17th among 31 sub-industries. The overall valuation of the pharmaceutical sector stands at 29.2 times earnings, placing it 10th among the primary industries [2][4][7]. - Key events include Fosun Pharma granting exclusive global rights for its oral GLP-1 drug to Pfizer, with potential total payments reaching $2.085 billion. Additionally, Eli Lilly's GLP-1/GIP/GCGR agonist Retatrutide showed promising Phase III clinical data, achieving a weight loss of 28.7% over 68 weeks [3][14][17]. - The report highlights significant mergers and acquisitions, such as Sobi's acquisition of Arthrosi for $950 million upfront and $550 million in milestone payments, and Zhaoli Pharmaceutical's planned acquisition of a multi-trace element injection asset group for approximately RMB 356 million [3][15][22]. Market Performance - The pharmaceutical index decreased by 1.0% this week, while the Shanghai Composite Index fell by 0.3%. The overall performance of the pharmaceutical sector was ranked 17th among 31 sub-industries [2][4][6]. - The report details the performance of various sub-sectors, with notable declines in medical circulation (-4.2%), offline pharmacies (-4.3%), and blood products (-4.1%), while medical R&D outsourcing saw an increase of 3.7% [7][11]. Recent Key Events - The report discusses recent business developments, including the approval of Shanghai Pharma's new drug, and the change of control at Tailong Pharmaceutical, which will now be under Jiang Pharmaceutical Holdings [20][22]. - It also notes the IPO application of Shiyao Innovation, which was accepted with a market value of RMB 47.9 billion, focusing on health-related sectors and innovative drugs [23]. Company Valuation - The report provides a valuation table for key companies in the pharmaceutical sector, indicating projected earnings per share (EPS) and price-to-earnings (PE) ratios for 2025 to 2027. For instance, Mindray Medical is projected to have a PE of 23 in 2025, while Hengrui Medicine is expected to have a PE of 48 [29].

Core Insights - The pharmaceutical industry is experiencing a surge in innovative products, with clear domestic demand and significant potential for international expansion [4][14][25] - Investment opportunities are concentrated in innovative drugs and their supply chains, with a notable performance from CRO/CMO and chemical pharmaceuticals [9][15][17] - The report emphasizes the importance of innovation as the primary solution to industry challenges, driven by stable demand and supportive policies [26][32][41] Industry Overview - The pharmaceutical sector has faced revenue declines, with a 0.9% year-on-year decrease in revenue for the first three quarters of 2025, and net profit down by 2.2% [15][16] - The innovative drug sector has outperformed, with CRO/CMO and chemical pharmaceuticals showing net profit growth of 31.0% and 16.6% respectively [17][18] - The overall market is characterized by low fund holdings and historical valuation bottoms, indicating high investment value [20][25] Demand and Payment Dynamics - The demand for healthcare services is steadily increasing, with a projected 5% growth in total medical visits and hospital admissions in 2024 [26][28] - The aging population is expected to drive long-term demand, with 220 million people aged 65 and above by 2050 [28][30] - The medical insurance fund's income growth has outpaced expenditure growth, leading to a significant increase in fund reserves [32][36] Financing and Market Trends - The IPO market for healthcare has rebounded, with 28 IPOs in the first three quarters of 2025, a 100% increase from the previous year [42][43] - License-out transactions have surged, with transaction numbers increasing by 41% and total amounts reaching $92 billion, indicating a robust market for innovative drug licensing [48][50] - The number of IND applications and new clinical trials for innovative drugs has been steadily increasing, with a notable rise in NDA approvals [53][57] Technological Advancements - The report highlights the emergence of new technologies such as ADC and small nucleic acids, with domestic companies leading in these areas [60] - The focus on dual antibodies and GLP-1 drugs is expected to drive significant growth, with multiple development directions emerging [9][60] - The report notes that domestic companies are increasingly recognized for their innovative capabilities, particularly in the ADC space [60]

来源：智通财经 智通财经12月12日讯（编辑 冯轶）智通财经为您带来今日港股重要公告 1）公司要闻 中远海能(01138.HK)：与大连中远海运重工、扬州中远海运重工及广东中远海运重工就建造一艘乙烯船 和十八艘油轮订立造船合约，总代价为人民币78.82亿元。 中国环境资源(01130.HK)：拟900万元收购四川源莱顺再生资源有限公司90%股权。 众安在线(06060.HK)：前11月累计原保险保费收入总额约为人民币329.04亿元。 富力地产(02777.HK)：前11个月总销售收入约127亿元，同比增长24.63%。 亿达中国(03639.HK)：前11个月合约销售金额约为6.81亿元，同比减少23.22% 卡森国际(00496.HK)：与供应商订立钢结构采购合约，涉资4353.66万元。 拨康视云-B(02592.HK)：成功举行CBT-004的第2期临床试验后会议。 复宏汉霖(02696.HK)：汉斯状®联合化疗用于胃癌新辅助/辅助治疗的上市注册申请获国家药监局受理， 并已纳入优先审评 石药集团(01093.HK)：多恩益®(盐酸伊立替康脂质体注射液)的新适应症获上市批准，联合用于转移性 胰腺癌患者的 ...